Table 4 Relationships between response to treatment and CYP2D6*10 allelic mutation
From: Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone
| Â | TT (26) | CT (21) | Statistics | P |
|---|---|---|---|---|
PANSS0 – week 4 | 20.5 (12.0, 28.2) | 19.0 (10.5, 35.0) | 1.357 | 0.645 |
PANSS0 – week 8 | 27.0 (19.0, 32.0) | 30.0 (17.0, 39.5) | 4.287 | 0.235 |
BPRS0 – week4 | 34.0 (28.8, 40.0) | 32.5 (30.8, 34.2) | 15.136 | 0.291 |
BPRS0 – week8 | 29.0 (27.0, 34.0) | 28.0 (26.3, 30.0) | 4.667 | 0.040 |
CGI-S0 – week4 | 4.0 (3.0, 4.0) | 3.5 (3.0, 4.0) | − 1.392 | 0.164 |
CGI-S0 – week 8 | 3.0 (2.0, 3.0) | 2.0 (2.0, 3.0) | −0.125 | 0.900 |
CGI-I2 – week 4 | −0.5 (−1.0, 0.0) | 0.0 (− 1.0, 0.0) | − 0.599 | 0.549 |
CGI-I2 – week 8 | 0.0 (−1.0, 1.0) | 0.0 (− 1.0, 1.0) | −3.84 | 0.701 |